Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, October 01, 2014
Technology Networks
 
Register | Sign in
Home Page
  Permissions

Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd

To obtain this permission contact:
Technology Networks Ltd
Unit 6, Woodview
Bull Lane
Acton
Sudbury
CO10 0FD, U.K.

In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved.

The information and data included in the TechnologyNetworks.com WWW site, and all its affiliated websites and associated email newsletters, have been compiled from a variety of sources, and are subject to change without notice. Technology Networks Ltd. makes no warranties or representations whatsoever regarding the quality, content, completeness, or adequacy of this information and data.

Technology Networks Ltd. specifically disclaims all warranties with respect to this WWW site, email newsletters or your use thereof, express, implied, or otherwise, including without limitation, all warranties of merchantability and fitness for a particular purpose. Technology Networks Ltd shall not be liable for any special, incidental, or consequential damages, including, without limitation, lost revenues, lost profits, or loss of prospective economic advantage, resulting from the use or misuse of this site, or the information therein.

Scientific News
Biologists Find An Early Sign Of Cancer
Patients show boost in certain amino acids years before diagnosis of pancreatic cancer.
Researchers Develop New DNA Sequencing Method to Diagnose Tuberculosis
Teams aim to test the metagenomics technique on a wide range of samples.
Inivata Raises £4m to Realize the Potential of ctDNA Analysis
New spin-out from Cancer Research UK launched with funding from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Blood Test May Help Determine Psychosis Risk
A study led by University of North Carolina at Chapel Hill researchers represents an important step forward in the accurate diagnosis of people who are experiencing the earliest stages of psychosis.
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles
Study reveals personalized risks for expansion from parent to child.
Blood Test To Diagnose Depression
Test identifies nine blood markers tied to depression; predicts who will benefit from therapy.
Study Aims to Develop Breath Test for COPD
A new clinical iniative, lead by NYU Langone Medical Center, aims to determine a breath test’s effectiveness to identify volatile organic compounds (VOCs) in human breath that are biomarkers of chronic obstructive pulmonary disease (COPD).
More People Testing Positive for Chikungunya Virus in the U.S.
Clinical testing volume and positivity rate both grew after the first case of the infectious disease spread to Western Hemisphere this year.
Clinical Utility of Myriad myPath(TM) Melanoma Test Demonstrated
Test reduced indeterminate cases by 76 percent and changed treatment in 35 percent of cases.
Sequencing Identifies Gene Variant Responsible for Lupus
Research demonstrates it is feasible to identify the individual causes of lupus in patients by using DNA sequencing, allowing doctors to target specific treatments to individual patients.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv